Synonym name:
Catalogue No.: BP0892
Cas No.: 848784-85-0
Formula: C₄₇H₇₆O₁₇
Mol Weight: 913.108
Botanical Source: Pulsatilla cernum and Pulsatilla koreana

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.

For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Pulsatilla saponin D (hereinafter referred to as PSD) is a type of medicinal herb derived from the Chinese medicinal herb Pulsatilla (Pulsatilla chinensis), a plant of the genus Anemones ) natural triterpene saponin products from the root. In recent years, with the deepening pharmacological research of natural products, PSD has attracted widespread attention due to its remarkable antitumor activity, especially its potential in colon cancer treatment. As one of the malignant tumors with high incidence and mortality rates worldwide, colon cancer urgently needs to develop new, highly effective, and low-toxicity treatments. With its unique molecular structure and multi-target mechanism, PSD offers new ideas for molecular targeted therapy of colon cancer.

This paper aims to systematically review the chemical structure and physicochemical properties of PSD, plant origin and extraction process, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and to explore its clinical application prospects and development directions, providing theoretical basis and reference for subsequent basic and clinical research.

Chemical structure and physicochemical properties

PSD has a chemical structure belonging to the triterpene saponin class, with the molecular formula C_48H_76O_17 and a molecular weight of 913.1080 Da. Its structural core is the pentacyclic triterpene parent nucleus, which connects multiple glycosyl residues to form a typical saponin backbone. The LogP value of PSD was 1.8682, indicating moderate hydrophobicity, which is beneficial for cell membrane permeability. Its polar surface area (TPSA) reaches 274.75 Ų, indicating strong molecular polarity that may affect oral absorption and bioavailability.

Water solubility is 0.1455 mg/mL, making it a low-solubility compound, suggesting the need for appropriate solubility enhancement strategies in drug formulation development. PSD lacks the ability to penetrate the blood-brain barrier, suggesting its role is mainly limited to peripheral tissues. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames mutagenic test result was 0.0, indicating a low genotoxicity risk and meeting basic safety requirements.

Plant Origins and Extraction Methods

PSD is mainly extracted from the root of the medicinal herb Pulsatilla chinensis. The White-headed Elder is a perennial herbaceous plant of the Ranunculaceae family, genus Anemonetum, widely distributed in northern China. Its root contains abundant triterpene saponin compounds, which are important medicinal materials in traditional Chinese medicine for clearing heat, detoxifying, reducing swelling, and relieving pain.

Common methods for extracting PSD include solvent extraction, column chromatography separation, and high-performance liquid chromatography (HPLC) purification. Typically, ethanol or methanol is used for reflux extraction, followed by separation and purification by silica gel column chromatography or reversed-phase C18 column. In recent years, the application of ultrasound-assisted extraction and supercritical fluid extraction technologies has improved the extraction efficiency and purity of PSD. In addition, liquid chromatography-mass spectrometry (LC-MS) technology plays an important role in qualitative and quantitative analysis of PSD.

Pharmacological activity research

Pharmacological activity studies of PSD mainly focus on its antitumor effects, especially its manifestations in colon cancer models. In vitro experiments have shown that PSD can significantly inhibit the proliferation of various colon cancer cell lines, induce apoptosis, and suppress tumor cell migration and invasion capabilities. In vivo animal model studies further confirmed PSD's inhibitory effect on colon cancer, manifested as tumor shrinkage and reduced metastasis.

In addition to its anticancer activity, PSD also exhibits various biological activities such as anti-inflammation, immunomodulatory, and antioxidant properties, which may synergistically enhance its anti-tumor effects. Especially in regulating the tumor microenvironment and suppressing tumor-related inflammatory factors, PSD demonstrates unique advantages.

Mechanism of action and molecular targets

The mechanism of PSD's anti-colon cancer action involves multiple signaling pathways and key molecular targets, reflecting its multi-target and multi-pathway regulation characteristics. The main targets include:

• AMPK (PRKAA1) :P SD activates the AMPK signaling pathway, promotes regulation of energy metabolism, induces autophagy and apoptosis in tumor cells, and inhibits cell proliferation.
• BCL2:P SD downregulates the expression of the anti-apoptotic protein BCL2, disrupting intracellular anti-apoptotic balance and promoting mitochondrial pathway-mediated apoptosis.
• STAT3: By inhibiting STAT3 phosphorylation and nuclear translocation, PSD blocks tumor cell proliferation, survival, and immune escape mechanisms.
• ABCB1:P SD inhibits the function of the multidrug resistance protein ABCB1, enhances the accumulation of chemotherapy drugs within tumor cells, and reverses drug resistance.
• ALOX5: By inhibiting the fatty acid-metabolizing enzyme ALOX5, PSD weakens the inflammatory response and proliferation signals of tumor cells.
• LCK:P SD regulates LCK kinase activity and affects T cell function in the tumor immune microenvironment.
• TOP1:P SD inhibits topoisomerase I (TOP1), blocking DNA replication and transcription, and inducing tumor cell death.
• RELA (NF-κB p65) :P SD inhibits the NF-κB signaling pathway, reduces the expression of pro-inflammatory factor TNF, and alleviates tumor-related inflammation.
• MAPK1: By regulating the MAPK signaling pathway, PSD intervenes in cell proliferation and apoptosis.
• TNF:P SD regulates tumor necrosis factor (TNF) levels, affecting tumor cell immune responses and apoptosis.

In summary, PSD regulates tumor cell survival, proliferation, apoptosis, and microenvironment through synergistic multi-target and multi-pathway effects, exerting its comprehensive anti-colon cancer effect.

Druggability evaluation and pharmacokinetics

From the perspective of druggability, PSD has a large molecular weight and strong polarity, which limits its oral bioavailability. The LogP is moderate, which facilitates cell membrane penetration, but its high TPSA value and low water solubility may limit its absorption. The blood-brain barrier penetration capacity is low, reducing the risk of central nervous system toxicity.

In terms of safety, PSD does not inhibit hERG channels, reducing the risk of cardiotoxicity; Ames test is negative, genotoxicity is low, meeting drug safety requirements.

Currently, pharmacokinetic data on PSD are relatively limited. Preliminary studies indicate that PSD is widely distributed in the body, mainly metabolized through the liver, with excretion routes including bile and urine. Its half-life is moderate, suggesting it is suitable for multiple doses to maintain effective concentrations. In the future, systematic pharmacokinetic and toxicological studies are needed to optimize dosing regimens and dosage form design.

Prospects and outlooks for clinical applications

PSD, as a natural product with multi-target antitumor activity, demonstrates promising clinical application potential. Its advantages in colon cancer treatment are mainly reflected in the following aspects:

1. Multi-target synergistic anti-cancer :P SD overcomes the tendency for single-target drugs to develop resistance by regulating multiple key molecules and signaling pathways.
2. High safety: No obvious genotoxicity or cardiotoxicity, suitable for long-term use.
3. Adjuvant chemotherapy potential:P SD's inhibitory effect on the multidrug resistance protein ABCB1 helps enhance chemotherapy efficacy and reduce resistance rates.
4. Immunomodulatory effect: By modulating immune cells in the tumor microenvironment, it enhances the body's anti-tumor immune response.

However, clinical translation of PSD still faces challenges. These mainly include its low water solubility and limitations in oral bioavailability, a lack of systematic preclinical toxicology and pharmacokinetic data, and the lack of large-scale clinical trials yet to be conducted. Future research should focus on:

• Optimizing dosage forms and administration routes to improve bioavailability;
• In-depth analysis of mechanisms of action, clarification of key targets and signaling pathways;
• Conduct systematic safety evaluations and pharmacokinetic studies;
• Design multicenter, randomized controlled clinical trials to verify efficacy and safety.

In addition, combining modern drug design technologies, such as nanocarriers, drug eutectics, and structural modifications, may further enhance the properties and clinical value of PSD.

Conclusion

Pulsatilla saponin D, a triterpene saponin derived from the traditional Chinese medicine Baitouweng, has become a hot topic in natural product pharmacology research due to its remarkable anti-colon cancer activity and multi-target mechanism. Its unique molecular structure endows it with excellent bioactivity and safety, demonstrating broad clinical application prospects.

In the future, based on systematic pharmacological research and modern drug development technologies, PSD is expected to break through existing treatment bottlenecks and become a novel candidate drug for colon cancer and other tumor treatments. Ongoing efforts in basic research and clinical translation will lay a solid foundation for the drug development of PSD and promote innovative development of natural products in the field of anti-tumor treatment.